BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 242] [Article Influence: 92.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Lu J, Xu Q, Chen B, Shen L. The association between serum folate and ultrasound - defined hepatic steatosis. Ann Med 2023;55:456-62. [PMID: 36647694 DOI: 10.1080/07853890.2023.2168042] [Reference Citation Analysis]
2 Lopez A, Aguilar J. A Data Analysis Smart System for the Optimal Deployment of Nanosensors in the Context of an eHealth Application. Algorithms 2023;16:81. [DOI: 10.3390/a16020081] [Reference Citation Analysis]
3 Darmadi D, Pakpahan C, Ruslie RH, Amanda B, Ibrahim R. The sex life of male patients with cirrhosis and its organic factors: What we have got so far? PLoS One 2023;18:e0280915. [PMID: 36730272 DOI: 10.1371/journal.pone.0280915] [Reference Citation Analysis]
4 Zhang R, Li P, Guo P, Zhou J, Wan J, Yang C, Zhou J, Liu Y, Shi S. A Pharmacokinetic Drug-Drug Interactions Study between Entecavir and Hydronidone, a Potential Novel Antifibrotic Small Molecule, in Healthy Male Volunteers. Adv Ther 2023;40:658-70. [PMID: 36477590 DOI: 10.1007/s12325-022-02377-x] [Reference Citation Analysis]
5 Murphy WA, Adiwidjaja J, Sjöstedt N, Yang K, Beaudoin JJ, Spires J, Siler SQ, Neuhoff S, Brouwer KLR. Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Clin Pharmacol Ther 2023;113:275-97. [PMID: 35429164 DOI: 10.1002/cpt.2614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Frost KL, Jilek JL, Sinari S, Klein RR, Billheimer D, Wright SH, Cherrington NJ. Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination. Drug Metab Dispos 2023;51:155-64. [PMID: 36328481 DOI: 10.1124/dmd.122.001038] [Reference Citation Analysis]
7 Bachtler N, Torres S, Ortiz C, Schierwagen R, Tyc O, Hieber C, Berres ML, Meier C, Kraus N, Zeuzem S, Nijmeijer B, Pronk S, Trebicka J, Klein S. The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells. PLoS One 2023;18:e0270288. [PMID: 36719899 DOI: 10.1371/journal.pone.0270288] [Reference Citation Analysis]
8 Feng L, Lu Y, Ren S, Liang H, Wei L, Jiang J. Development and validation of a dynamic online nomogram for predicting acute kidney injury in cirrhotic patients upon ICU admission. Front Med 2023;10. [DOI: 10.3389/fmed.2023.1055137] [Reference Citation Analysis]
9 Li Z, Zhou X, Han L, Shi M, Xiao H, Lin M, Chi X. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis. J Gastrointest Surg 2023. [PMID: 36703021 DOI: 10.1007/s11605-022-05528-1] [Reference Citation Analysis]
10 Yokoo T, Masaki N, Parikh ND, Lane BF, Feng Z, Mendiratta-Lala M, Lee CH, Khatri G, Marsh TL, Shetty K, Dunn CT, Al-Jarrah T, Aslam A, Davenport MS, Gopal P, Rich NE, Lok AS, Singal AG. Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma. Radiology 2023;:220917. [PMID: 36692401 DOI: 10.1148/radiol.220917] [Reference Citation Analysis]
11 Wang W, Huang Q, Liao Z, Zhang H, Liu Y, Liu F, Chen X, Zhang B, Chen Y, Zhu P. ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner. Exp Hematol Oncol 2023;12:1. [PMID: 36609413 DOI: 10.1186/s40164-022-00370-2] [Reference Citation Analysis]
12 Ng CH, Chan KE, Muthiah M, Tan C, Tay P, Lim WH, Tan DJH, Fu CE, Yong JN, Wong ZY, Koh B, Chew NW, Syn N, Huang DQ, Young Dan Y, Siddiqui MS, Sanyal AJ, Noureddin M. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology 2023. [PMID: 36645228 DOI: 10.1097/HEP.0000000000000043] [Reference Citation Analysis]
13 Lee DU, Hastie DJ, Lee KJ, Addonizio E, Fan GH, Chou H, Jung D, Lee K, Lominadze Z. The trends in cost associated with liver transplantation in the US: analysis of weighted hospital data. Liver Transpl 2023. [PMID: 36724884 DOI: 10.1097/LVT.0000000000000063] [Reference Citation Analysis]
14 Tse JR, Shen L, Tiyarattanachai T, Bird KN, Liang T, Yoon L, Kamaya A. Positive predictive value of LI-RADS US-3 observations: multivariable analysis of clinical and imaging features. Abdom Radiol (NY) 2023;48:271-81. [PMID: 36253490 DOI: 10.1007/s00261-022-03681-4] [Reference Citation Analysis]
15 Salimov UR, Olegovich SI, Aliakseevich KA, Nikolaevna HT, Mikhailovich FA, Eugenievich SA, Rummo OO. GUT MICROBIOTA MIGHT INFLUENCE THE RISK OF REJECTION AFTER LIVER TRANSPLANTATION. Journal of Liver Transplantation 2023. [DOI: 10.1016/j.liver.2023.100140] [Reference Citation Analysis]
16 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
17 Chawla S, Das A. Preclinical-to-clinical innovations in stem cell therapies for liver regeneration. Curr Res Transl Med 2023;71:103365. [PMID: 36427419 DOI: 10.1016/j.retram.2022.103365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol 2023;78:207-16. [PMID: 36089157 DOI: 10.1016/j.jhep.2022.08.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Stern JI, Datta S, Chiang CC, Garza I, Vieira DL, Robertson CE. Narrative review of migraine management in patients with renal or hepatic disease. Headache 2023;63:9-24. [PMID: 36709407 DOI: 10.1111/head.14437] [Reference Citation Analysis]
20 Uddin MM, Mir T, Briasoulis A, Akintoye E, Adegbala O, Shafi I, Qureshi WT, Afonso LC. Clinical outcomes and 30-day readmissions associated with high-output heart failure. Hellenic J Cardiol 2023;69:24-30. [PMID: 36273803 DOI: 10.1016/j.hjc.2022.10.004] [Reference Citation Analysis]
21 Xue X, Zhao X, Wang J, Wang C, Ma C, Zhang Y, Li Y, Peng C. Carthami flos extract against carbon tetrachloride-induced liver fibrosis via alleviating angiogenesis in mice. Phytomedicine 2023;108:154517. [DOI: 10.1016/j.phymed.2022.154517] [Reference Citation Analysis]
22 Kwong AJ, Zahr NM. Serum biomarkers of liver fibrosis identify globus pallidus vulnerability. NeuroImage: Clinical 2023. [DOI: 10.1016/j.nicl.2023.103333] [Reference Citation Analysis]
23 Guo Z, Liang J. Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma. Lipids Health Dis 2022;21:146. [PMID: 36581927 DOI: 10.1186/s12944-022-01759-y] [Reference Citation Analysis]
24 Liu Y, Song J, Wang W, Zhang K, Yang J, Wen J, Meng X, Gao J, Wang J, Shao C, Tang YD. Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients. Thromb J 2022;20:82. [PMID: 36578015 DOI: 10.1186/s12959-022-00441-8] [Reference Citation Analysis]
25 Canivet CM, Boursier J. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022? Diagnostics (Basel) 2022;13. [PMID: 36611384 DOI: 10.3390/diagnostics13010091] [Reference Citation Analysis]
26 Martínez Montalvo CM, Gutierrez LC, Rojas DV, Saummet SV, Galindo Escucha CS, Camacho RC, Varón Puerta A. Variables hemodinámicas cardíacas y desenlaces postrasplante hepático en un centro de referencia de trasplantes en Colombia a 2600 metros sobre el nivel del mar. Rev colomb Gastroenterol 2022;37:390-401. [DOI: 10.22516/25007440.923] [Reference Citation Analysis]
27 Miwa T, Hanai T, Imai K, Takai K, Shiraki M, Hayashi H, Shimizu S, Nishigaki Y, Tomita E, Shimizu M. Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study. J Clin Med 2022;11. [PMID: 36555935 DOI: 10.3390/jcm11247318] [Reference Citation Analysis]
28 Johnson AW, Golzarri Arroyo L, Mahendraker N, Hosty J, Kroenke K. Hospital Opioid Usage and Adverse Events in Patients With End-Stage Liver Disease. J Pain Symptom Manage 2022:S0885-3924(22)01002-8. [PMID: 36496114 DOI: 10.1016/j.jpainsymman.2022.11.026] [Reference Citation Analysis]
29 Fang K, Yang Q, Lin Y, Zheng L, Wang HL, Wu J. Global cirrhosis prevalence trends and attributable risk factors-an ecological study using data from 1990-2019. Liver Int 2022;42:2791-9. [PMID: 36074563 DOI: 10.1111/liv.15421] [Reference Citation Analysis]
30 Lu G, Du R, Feng B, Wang J, Zhang F, Pei J, Wang Y, Shang Y. A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. JIR 2022;Volume 15:6729-6743. [DOI: 10.2147/jir.s390113] [Reference Citation Analysis]
31 Sempokuya T, Warner J, Azawi M, Nogimura A, Wong LL. Current status of disparity in liver disease. World J Hepatol 2022; 14(11): 1940-1952 [DOI: 10.4254/wjh.v14.i11.1940] [Reference Citation Analysis]
32 Ha A, Saleh ZM, Serper M, Tapper EB. Falls are an underappreciated driver of morbidity and mortality in cirrhosis. Clin Liver Dis (Hoboken) 2022;20:146-50. [PMID: 36447902 DOI: 10.1002/cld.1246] [Reference Citation Analysis]
33 Hundt MA, Tien C, Kahn JA. Addressing sex-based disparities in liver transplantation. Current Opinion in Organ Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/mot.0000000000001040] [Reference Citation Analysis]
34 Liu X, Ma H, Wu R, Wang H, Xu H, Li S, Wang G, Lv G, Niu J. Identification of Liver Fibrosis-Related MicroRNAs in Human Primary Hepatic Stellate Cells Using High-Throughput Sequencing. Genes (Basel) 2022;13. [PMID: 36553468 DOI: 10.3390/genes13122201] [Reference Citation Analysis]
35 Muraki P, Lee C, Patel N, Arevalo A, Ohtake S, Mendhiratta N, Chamie K, Agopian V, Benharash P, Shuch B. Perioperative Nephrectomy Outcomes for Patients with Liver Disease: Implications for Liver Transplant Candidates. Urology 2022:S0090-4295(22)00907-4. [PMID: 36403677 DOI: 10.1016/j.urology.2022.10.016] [Reference Citation Analysis]
36 Enciso N, Amiel J, Fabián-domínguez F, Pando J, Rojas N, Cisneros-huamaní C, Nava E, Enciso J. Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies. Analytical Cellular Pathology 2022;2022:1-9. [DOI: 10.1155/2022/2841894] [Reference Citation Analysis]
37 Yan T, Huang C, Lei J, Guo Q, Su G, Wu T, Jin X, Peng C, Cheng J, Zhang L, Liu Z, Kin T, Ying F, Liangpunsakul S, Li Y, Lu Y. Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patients. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.976445] [Reference Citation Analysis]
38 Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol 2022; 28(41): 5910-5930 [DOI: 10.3748/wjg.v28.i41.5910] [Reference Citation Analysis]
39 Peng H, Hou M, Wu Z, Wang J, Zhou M, Zhuang X, Xing J, Tao Q, Huang L, Zhou F, Zhang S, Feng Q, Hou Y, Yu Q. Plasma exosomal miR-122 regulates the efficacy of metformin via AMPK in type 2 diabetes and hepatocellular carcinoma. Heliyon 2022. [DOI: 10.1016/j.heliyon.2022.e11503] [Reference Citation Analysis]
40 How GY, Pua U. Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic. Journal of Interventional Medicine 2022;5:180-183. [DOI: 10.1016/j.jimed.2022.09.004] [Reference Citation Analysis]
41 Goeppert B, Roessler S. New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation. Hepatology 2022;76:1237-9. [PMID: 35384001 DOI: 10.1002/hep.32509] [Reference Citation Analysis]
42 Shakerinasab N, Azizi M, Mansourian M, Sadeghi H, Salaminia S, Abbasi R, Shahaboddin ME, Doustimotlagh AH. Empagliflozin Exhibits Hepatoprotective Effects Against Bile Duct Ligation-induced Liver Injury in Rats: A Combined Molecular Docking Approach to In Vivo Studies. Curr Pharm Des 2022;28:3313-23. [PMID: 36305136 DOI: 10.2174/1381612829666221027112239] [Reference Citation Analysis]
43 Kaltenbach MG, Tapper EB. High Preoperative Fibrosis-4 Index Is Associated With Postoperative Mortality: An Argument to Look for Advanced Liver Disease Before Surgery. Anesth Analg 2022;135:954-6. [PMID: 36269985 DOI: 10.1213/ANE.0000000000006130] [Reference Citation Analysis]
44 Mahmoudi A, Atkin SL, Jamialahmadi T, Banach M, Sahebkar A. Effect of Curcumin on Attenuation of Liver Cirrhosis via Genes/Proteins and Pathways: A System Pharmacology Study. Nutrients 2022;14:4344. [DOI: 10.3390/nu14204344] [Reference Citation Analysis]
45 Matuz-Mares D, Vázquez-Meza H, Vilchis-Landeros MM. NOX as a Therapeutic Target in Liver Disease. Antioxidants (Basel) 2022;11:2038. [PMID: 36290761 DOI: 10.3390/antiox11102038] [Reference Citation Analysis]
46 Garbuzenko DV. Current strategies for targeted therapy of liver fibrosis. Bûll sib med 2022;21:154-165. [DOI: 10.20538/1682-0363-2022-3-154-165] [Reference Citation Analysis]
47 Wang R, Hu Y, Huang L, He Q, Wang Y, Zhang L, Luo J. In-Vivo Monitoring of Liver Regeneration by Ultrasound Localization Microscopy: A Feasibility Study. 2022 IEEE International Ultrasonics Symposium (IUS) 2022. [DOI: 10.1109/ius54386.2022.9958263] [Reference Citation Analysis]
48 Ha Y, Jeong I, Kim TH. Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives. Biomedicines 2022;10:2530. [PMID: 36289791 DOI: 10.3390/biomedicines10102530] [Reference Citation Analysis]
49 Rabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia-Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model. Hepatol Commun 2022;6:3324-34. [PMID: 36214066 DOI: 10.1002/hep4.2091] [Reference Citation Analysis]
50 Matthias Buechter, Guido Gerken. Liver Function—How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. J Pers Med 2022;12:1657. [PMID: 36294796 DOI: 10.3390/jpm12101657] [Reference Citation Analysis]
51 Dong FC, Tan WT, Wang XB, Zheng X, Huang Y, Li BL, Meng ZJ, Gao YH, Qian ZP, Liu F, Lu XB, Shang J, Shi Y, Zheng YB, Yan HD, Zhang Y, Xu BY, Hou YX, Zhang Q, Xiong Y, Zou CC, Chen J, Huang ZB, Jiang XH, Luo S, Chen YY, Gao N, Liu CY, Yuan W, Mei X, Li J, Li T, Zheng RJ, Zhou XY, Chen JJ, Deng GH, Mei XX, Zhang WT, Li H. The neutrophil-to-lymphocyte ratio represents a systemic inflammation marker and reflects the relationship with 90-day mortality in non-cirrhotic chronic severe hepatitis. J Dig Dis 2022;23:587-96. [PMID: 36326787 DOI: 10.1111/1751-2980.13143] [Reference Citation Analysis]
52 Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J, Zhu D, Wang H, Liu Y, Luo J, Li X. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnology 2022;20:432. [PMID: 36183106 DOI: 10.1186/s12951-022-01636-x] [Reference Citation Analysis]
53 Hu R, Liang X, Li Q, Liu Y, Shi Z. Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/4869732] [Reference Citation Analysis]
54 Han K, Tan K, Shen J, Gu Y, Wang Z, He J, Kang L, Sun W, Gao L, Gao Y. Machine learning models including insulin resistance indexes for predicting liver stiffness in United States population: Data from NHANES. Front Public Health 2022;10:1008794. [PMID: 36211651 DOI: 10.3389/fpubh.2022.1008794] [Reference Citation Analysis]
55 Zhang Y, Hua L, Lin C, Yuan M, Xu W, Raj D. A, Venkidasamy B, Cespedes-acuna CL, Nile SH, Yan G, Zheng H. Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway. Front Pharmacol 2022;13:937484. [DOI: 10.3389/fphar.2022.937484] [Reference Citation Analysis]
56 de Mattos ÂZ, Simonetto DA, Terra C, Farias AQ, Bittencourt PL, Pase THS, Toazza MR, de Mattos AA, Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group. Albumin administration in patients with cirrhosis: Current role and novel perspectives. World J Gastroenterol 2022; 28(33): 4773-4786 [DOI: 10.3748/wjg.v28.i33.4773] [Reference Citation Analysis]
57 Shchyokotova AP. Liver cirrhosis. Perm Medical Journal 2022;39:41-57. [DOI: 10.17816/pmj39441-57] [Reference Citation Analysis]
58 Khaderi S, Kanwal F. Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology 2022;76:546-8. [PMID: 35388520 DOI: 10.1002/hep.32512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Niezen S, Mehta M, Jiang ZG, Tapper EB. Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clin Gastroenterol Hepatol 2022;20:2032-2040.e6. [PMID: 34626832 DOI: 10.1016/j.cgh.2021.09.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
60 Rossi D, D’avila AF, Galant LH, Marroni CA. EXERCISE IN THE PHYSICAL REHABILITATION OF CIRROTICS: A RANDOMIZED PILOT STUDY. Arq Gastroenterol 2022;59:408-413. [DOI: 10.1590/s0004-2803.202203000-73] [Reference Citation Analysis]
61 Moon AM, Ioannou GN. Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. Am J Gastroenterol 2022;117:1409-11. [PMID: 35973179 DOI: 10.14309/ajg.0000000000001897] [Reference Citation Analysis]
62 Cullaro G, Verna EC, McCulloch CE, Lai JC. Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types. Hepatology 2022;76:689-99. [PMID: 35298079 DOI: 10.1002/hep.32448] [Reference Citation Analysis]
63 Massironi S, Pirola L, Mulinacci G, Ciaccio A, Viganò C, Palermo A, Zilli A, Invernizzi P, Danese S. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks. Inflamm Bowel Dis 2022:izac189. [PMID: 36040402 DOI: 10.1093/ibd/izac189] [Reference Citation Analysis]
64 Alhyari A, Görg C, Alakhras R, Dietrich CF, Trenker C, Safai Zadeh E. HCC or Something Else? Frequency of Various Benign and Malignant Etiologies in Cirrhotic Patients with Newly Detected Focal Liver Lesions in Relation to Different Clinical and Sonographic Parameters. Diagnostics 2022;12:2079. [DOI: 10.3390/diagnostics12092079] [Reference Citation Analysis]
65 Lee HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022. [PMID: 35989555 DOI: 10.1002/hep.32741] [Reference Citation Analysis]
66 Domerecka W, Kowalska-kępczyńska A, Homa-mlak I, Michalak A, Mlak R, Mazurek M, Cichoż-lach H, Małecka-massalska T. The Usefulness of Extended Inflammation Parameters and Systemic Inflammatory Response Markers in the Diagnostics of Autoimmune Hepatitis. Cells 2022;11:2554. [DOI: 10.3390/cells11162554] [Reference Citation Analysis]
67 Johnston HE, Takefala TG, Kelly JT, Keating SE, Coombes JS, Macdonald GA, Hickman IJ, Mayr HL. The Effect of Diet and Exercise Interventions on Body Composition in Liver Cirrhosis: A Systematic Review. Nutrients 2022;14:3365. [DOI: 10.3390/nu14163365] [Reference Citation Analysis]
68 Liu S, Wu J, Chen P, Mohammed SAD, Zhang J, Liu S, Sameer Aga S. TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/4949148] [Reference Citation Analysis]
69 Pang J, Chen K, Chen S, Chen X. Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990-2019: a systematic analysis for the GBD 2019. Diabetol Metab Syndr 2022;14:112. [PMID: 35941673 DOI: 10.1186/s13098-022-00885-y] [Reference Citation Analysis]
70 Rodríguez-fragoso L, Rodríguez-lópez A, Sánchez-quevedo J. Models of Hepatotoxicity for the Study of Chronic Liver Disease. Animal Models and Experimental Research in Medicine [Working Title] 2022. [DOI: 10.5772/intechopen.106219] [Reference Citation Analysis]
71 Trivedi HD, Niezen S, Jiang ZG, Tapper EB. Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. Dig Dis Sci 2022;67:4215-22. [PMID: 34417922 DOI: 10.1007/s10620-021-07228-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Amin AN, Nguyen PH, Tapper EB. Missed diagnosis of cirrhosis in the inpatient setting. J Hosp Med 2022;17 Suppl 1:S1-7. [PMID: 35972039 DOI: 10.1002/jhm.12918] [Reference Citation Analysis]
73 Aniemeka C, Pillai AA. HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV. Dig Dis Sci 2022;67:3483-4. [PMID: 35288830 DOI: 10.1007/s10620-022-07434-7] [Reference Citation Analysis]
74 Enrique L, Graciela Z, Amirhossein S, Mayela R, Simental-mendía LE. Coffee consumption has no effect on circulating markers of liver function but increases adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutrition Research 2022. [DOI: 10.1016/j.nutres.2022.07.010] [Reference Citation Analysis]
75 Singal AG, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2022;20:1795-1802.e2. [PMID: 33662594 DOI: 10.1016/j.cgh.2021.02.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Lyagin I, Maslova O, Stepanov N, Efremenko E. Degradation of mycotoxins in mixtures by combined proteinous nanobiocatalysts: In silico, in vitro and in vivo. Int J Biol Macromol 2022;218:866-77. [PMID: 35907453 DOI: 10.1016/j.ijbiomac.2022.07.179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 White K, Tabah A, Ramanan M, Shekar K, Edwards F, Laupland KB. 90-day Case-Fatality in Critically ill Patients with Chronic Liver Disease Influenced by Presence of Portal Hypertension, Results from a Multicentre Retrospective Cohort Study. J Intensive Care Med 2022;:8850666221100408. [PMID: 35892180 DOI: 10.1177/08850666221100408] [Reference Citation Analysis]
78 Jang E. Hyperoside as a Potential Natural Product Targeting Oxidative Stress in Liver Diseases. Antioxidants 2022;11:1437. [DOI: 10.3390/antiox11081437] [Reference Citation Analysis]
79 Río Bártulos C, Senk K, Bade R, Schumacher M, Plath J, Kaiser N, Wiesinger I, Thurn S, Stroszczynski C, El Mountassir A, Planert M, Woetzel J, Wiggermann P. MELIF, a Fully Automated Liver Function Score Calculated from Gd-EOB-DTPA-Enhanced MR Images: Diagnostic Performance vs. the MELD Score. Diagnostics 2022;12:1750. [DOI: 10.3390/diagnostics12071750] [Reference Citation Analysis]
80 Afridi F, Mittal A, Pyrsopoulos N. Trends in Mortality and Health Care Burden of Cirrhotic Decompensation in Hospitalized Patients: A Nationwide Analysis. J Clin Gastroenterol 2022. [PMID: 35862058 DOI: 10.1097/MCG.0000000000001734] [Reference Citation Analysis]
81 Ye Y, Wang H, Gao J, Kostallari E. Editorial: Chronic Liver Disease: New Targets and New Mechanisms. Front Mol Biosci 2022;9:963630. [DOI: 10.3389/fmolb.2022.963630] [Reference Citation Analysis]
82 Somova DE, Galyan TN, Kulichkin AS, Filin AV, Khovrin VV. The system for assessing liver function according to magnetic resonance imaging with gadoxetic acid. SJCEM 2022;37:84-91. [DOI: 10.29001/2073-8552-2022-37-2-84-91] [Reference Citation Analysis]
83 Boichak MP, Ukrainian Military Medical Academy, 45, Gen. Almazova St., Kyiv 01010, Ukraine, Fedorova OO, Illyashenko YM, Zhurko MM, Antonov AB, Ukrainian Military Medical Academy, 45, Gen. Almazova St., Kyiv 01010, Ukraine, Military Medical Clinical Center of the Northern Region, 5, Kultury Str., Kharkiv 61000, Ukraine, Ukrainian Military Medical Academy, 45, Gen. Almazova St., Kyiv 01010, Ukraine, Military Medical Clinical Center of the Northern Region, 5, Kultury Str., Kharkiv 61000, Ukraine. Nonspecific Reactive Hepatitis – Unknown or Forgotten Diagnosis? (Short Review and Invitation to Discussion). Ukr ž med bìol sportu 2022;7:14-20. [DOI: 10.26693/jmbs07.03.014] [Reference Citation Analysis]
84 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol 2022;77:128-39. [PMID: 35139400 DOI: 10.1016/j.jhep.2022.01.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
85 Gao T, Liao W, Lin L, Zhu Z, Lu M, Fu C, Xie T. Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications. Phytomedicine 2022;102:154090. [DOI: 10.1016/j.phymed.2022.154090] [Reference Citation Analysis]
86 Lazo M, Martinez-Folgar K, Bilal U. Racial/Ethnic Disparities in Hepatocellular Carcinoma: The Role of Neighborhood Socioeconomic Deprivation. Cancer Epidemiol Biomarkers Prev 2022;31:1254-6. [PMID: 35775232 DOI: 10.1158/1055-9965.EPI-22-0378] [Reference Citation Analysis]
87 Schoenberger H, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, Olivares J, Parikh ND, Yopp AC, Marrero JA, Singal AG. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2022;20:1561-1569.e4. [PMID: 34119640 DOI: 10.1016/j.cgh.2021.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
88 Devaraj E, Perumal E, Subramaniyan R, Mustapha N. Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space. Hepatology 2022;76:275-85. [PMID: 34773651 DOI: 10.1002/hep.32239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
89 Nguyen SA, Merrill CD, Burrowes DP, Medellin GA, Wilson SR. Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADS. Radiographics 2022;42:1028-42. [PMID: 35486579 DOI: 10.1148/rg.210149] [Reference Citation Analysis]
90 Squires JH, Fetzer DT, Dillman JR. Practical Contrast Enhanced Liver Ultrasound. Radiologic Clinics of North America 2022. [DOI: 10.1016/j.rcl.2022.04.006] [Reference Citation Analysis]
91 Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72. [PMID: 35850495 DOI: 10.3350/cmh.2022.0186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Chu J, Cholankeril G, Yu X, Rana A, Natarajan Y, El-Serag HB, Kramer J, Kanwal F. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci 2022. [PMID: 35759159 DOI: 10.1007/s10620-022-07565-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 van Beekum CJ, Beckmann C, Semaan A, Manekeller S, Matthaei H, Braun L, Willis MA, Kalff JC, Vilz TO. Predictors of Morbidity and Mortality After Colorectal Surgery in Patients With Cirrhotic Liver Disease–A Retrospective Analysis of 54 Cases at a Tertiary Care Center. Front Med 2022;9:886566. [DOI: 10.3389/fmed.2022.886566] [Reference Citation Analysis]
94 Yang D, Su Y, Zhao F, Chen C, Zhao K, Xiong X, Ding Y. A Practical Nomogram and Risk Stratification System Predicting Cancer-Specific Survival for Hepatocellular Carcinoma Patients With Severe Liver Fibrosis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.920589] [Reference Citation Analysis]
95 Verma M, Brahmania M, Fortune BE, Asrani SK, Fuchs M, Volk ML. Patient-centered care: Key elements applicable to chronic liver disease. Hepatology 2022. [PMID: 35712801 DOI: 10.1002/hep.32618] [Reference Citation Analysis]
96 Malakar S, Roy SD, Das S, Sen S, Velásquez JD, Sarkar R. Computer Based Diagnosis of Some Chronic Diseases: A Medical Journey of the Last Two Decades. Arch Comput Methods Eng 2022;:1-43. [PMID: 35729963 DOI: 10.1007/s11831-022-09776-x] [Reference Citation Analysis]
97 Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World J Gastroenterol 2022; 28(21): 2361-2382 [DOI: 10.3748/wjg.v28.i21.2361] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
98 Kim HS, Shetty PB, Tsavachidis S, Dong J, Amos CI, El-Serag HB, Thrift AP. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00529-8. [PMID: 35680035 DOI: 10.1016/j.cgh.2022.05.020] [Reference Citation Analysis]
99 Chen L, Kong D, Xia S, Wang F, Li Z, Zhang F, Zheng S. Crosstalk Between Autophagy and Innate Immunity: A Pivotal Role in Hepatic Fibrosis. Front Pharmacol 2022;13:891069. [PMID: 35656309 DOI: 10.3389/fphar.2022.891069] [Reference Citation Analysis]
100 Li X, Gong M, Fu S, Zhang J, Wu S. Establishment of MELD-lactate clearance scoring system in predicting death risk of critically ill cirrhotic patients. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02351-5] [Reference Citation Analysis]
101 Niu L, Thiele M, Geyer PE, Rasmussen DN, Webel HE, Santos A, Gupta R, Meier F, Strauss M, Kjaergaard M, Lindvig K, Jacobsen S, Rasmussen S, Hansen T, Krag A, Mann M. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med 2022. [PMID: 35654907 DOI: 10.1038/s41591-022-01850-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
102 Sardar A, Parkash A, Merchant AA, Qamar B, Ayub F, Zehravi S. Etiology in Children Presented With Chronic Liver Disease in a Tertiary Care Hospital. Cureus. [DOI: 10.7759/cureus.25570] [Reference Citation Analysis]
103 Pan AY, Zilberstein NF, Farnan JM, McConville JF, Mikolajczyk AE. Recently Graduated Medical Students Lack Exposure to and Comfort with Chronic Liver Diseases. Dig Dis Sci 2022;67:2081-5. [PMID: 34365534 DOI: 10.1007/s10620-021-07182-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Dunne PDJ, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead J, Smith LA, Gaya DR, Forrest E, Stanley AJ. Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Aliment Pharmacol Ther 2022;55:1581-7. [PMID: 35322892 DOI: 10.1111/apt.16901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022;22:621-32. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Siemienowicz KJ, Filis P, Thomas J, Fowler PA, Duncan WC, Rae MT. Hepatic Mitochondrial Dysfunction and Risk of Liver Disease in an Ovine Model of “PCOS Males”. Biomedicines 2022;10:1291. [DOI: 10.3390/biomedicines10061291] [Reference Citation Analysis]
107 Zhang YY, Meng ZJ. Definition and classification of acute-on-chronic liver diseases. World J Clin Cases 2022; 10(15): 4717-4725 [DOI: 10.12998/wjcc.v10.i15.4717] [Reference Citation Analysis]
108 Niu L, Geyer PE, Gupta R, Santos A, Meier F, Doll S, Wewer Albrechtsen NJ, Klein S, Ortiz C, Uschner FE, Schierwagen R, Trebicka J, Mann M. Dynamic human liver proteome atlas reveals functional insights into disease pathways. Mol Syst Biol 2022;18:e10947. [PMID: 35579278 DOI: 10.15252/msb.202210947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Nattagh-Eshtivani E, Gheflati A, Barghchi H, Rahbarinejad P, Hachem K, Shalaby MN, Abdelbasset WK, Ranjbar G, Olegovich Bokov D, Rahimi P, Gholizadeh Navashenaq J, Pahlavani N. The role of Pycnogenol in the control of inflammation and oxidative stress in chronic diseases: Molecular aspects. Phytother Res 2022. [PMID: 35583807 DOI: 10.1002/ptr.7454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Sasso JM, Ambrose BJB, Tenchov R, Datta RS, Basel MT, DeLong RK, Zhou QA. The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments. J Med Chem 2022. [PMID: 35533054 DOI: 10.1021/acs.jmedchem.2c00024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Miao X, Sha T, Zhang W, Zhou H, Qiu C, Deng H, You Y, Ren J, Zhang X, Zheng R, Yin T. Liver Fibrosis Assessment by Viewing Sinusoidal Capillarization: US Molecular Imaging versus Two-dimensional Shear-Wave Elastography in Rats. Radiology 2022;:212325. [PMID: 35503015 DOI: 10.1148/radiol.212325] [Reference Citation Analysis]
112 Rich NE, Phen S, Desai N, Mittal S, Yopp AC, Yang JD, Marrero JA, Iyengar P, Infante RE, Singal AG. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol 2022;20:e1157-69. [PMID: 34555519 DOI: 10.1016/j.cgh.2021.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
113 Frost KL, Marie S, Cherrington NJ. Mechanistic Basis of Increased Susceptibility to Nephrotoxicants in Chronic Liver Disease. Current Opinion in Toxicology 2022. [DOI: 10.1016/j.cotox.2022.100347] [Reference Citation Analysis]
114 Ferreira S, Marroni CA, Stein JT, Rayn R, Henz AC, Schmidt NP, Carteri RB, Fernandes SA. Assessment of resting energy expenditure in patients with cirrhosis. World J Hepatol 2022; 14(4): 802-811 [DOI: 10.4254/wjh.v14.i4.802] [Reference Citation Analysis]
115 Garbuzenko DV. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis . World J Clin Cases 2022; 10(12): 3662-3676 [DOI: 10.12998/wjcc.v10.i12.3662] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Dewyse L, De Smet V, Verhulst S, Eysackers N, Kunda R, Messaoudi N, Reynaert H, van Grunsven LA. Improved Precision-Cut Liver Slice Cultures for Testing Drug-Induced Liver Fibrosis. Front Med (Lausanne) 2022;9:862185. [PMID: 35433753 DOI: 10.3389/fmed.2022.862185] [Reference Citation Analysis]
117 Ibrahim S, Fahim SA, Tadros SA, Badary OA. Suppressive effects of thymoquinone on the initiation stage of diethylnitrosamine hepatocarcinogenesis in rats. J Biochem Mol Toxicol 2022;:e23078. [PMID: 35437842 DOI: 10.1002/jbt.23078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Newman LA, Muller K, Rowland A. Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04256-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Luo J, Li L, Chang B, Zhu Z, Deng F, Hu M, Yu Y, Lu X, Chen Z, Zuo D, Zhou J. Mannan-Binding Lectin via Interaction With Cell Surface Calreticulin Promotes Senescence of Activated Hepatic Stellate Cells to Limit Liver Fibrosis Progression. Cell Mol Gastroenterol Hepatol 2022;14:75-99. [PMID: 35381393 DOI: 10.1016/j.jcmgh.2022.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Miyaaki H, Hiraoka A, Haraguchi M, Uojima H, Kawaratani H, Hiramatsu A, Hanai T, Hiasa Y, Yoshiji H, Okita K, Nakao K, Koike K. Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver-related complications. Hepatol Res 2022;52:364-70. [PMID: 34755420 DOI: 10.1111/hepr.13731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
121 Holczbauer Á, Wangensteen KJ, Shin S. Cellular origins of regenerating liver and hepatocellular carcinoma. JHEP Reports 2022;4:100416. [DOI: 10.1016/j.jhepr.2021.100416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
122 Carlessi R, Denisenko E, Boslem E, Koehn-gaone J, Main N, Abu Bakar NDB, Shirolkar GD, Jones M, Poppe D, Dwyer BJ, Jackaman C, Tjiam MC, Lister R, Karin M, Fallowfield JA, Kendall TJ, Forbes SJ, Olynyk JK, Yeoh G, Forrest ARR, Ramm GA, Febbraio MA, Tirnitz-parker JEE. Single Nucleus RNA Sequencing of Pre-Malignant Liver Reveals Disease-Associated Hepatocyte State with HCC Prognostic Potential.. [DOI: 10.1101/2022.03.25.485695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Tandoh KZ, Quaye O. Genetic associations in chronic hepatitis B infection: toward developing polygenic risk scores. Future Microbiol 2022. [PMID: 35332782 DOI: 10.2217/fmb-2021-0176] [Reference Citation Analysis]
124 Kanabekova P, Kadyrova A, Kulsharova G. Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro. Micromachines 2022;13:428. [DOI: 10.3390/mi13030428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
125 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
126 Kanwal F, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, Amos CI, Thrift AP, Gu X, Luster M, Al-Sarraj A, Ning J, El-Serag HB. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology 2022. [PMID: 35229329 DOI: 10.1002/hep.32434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
127 Khurana C, Bedi O. Proposed hypothesis of GSK-3 β inhibition for stimulating Wnt/β-catenin signaling pathway which triggers liver regeneration process. Naunyn Schmiedebergs Arch Pharmacol 2022;395:377-80. [PMID: 35076714 DOI: 10.1007/s00210-022-02207-5] [Reference Citation Analysis]
128 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541-9. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
129 Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. Asian perspective on NAFLD-associated HCC. J Hepatol 2022;76:726-34. [PMID: 34619251 DOI: 10.1016/j.jhep.2021.09.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
130 Huang AC, Grab J, Flemming JA, Dodge JL, Irani RA, Sarkar M. Pregnancies With Cirrhosis Are Rising and Associated With Adverse Maternal and Perinatal Outcomes. Am J Gastroenterol 2022;117:445-52. [PMID: 34928866 DOI: 10.14309/ajg.0000000000001590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Soriano G. Des probiotiques pour l’encéphalopathie hépatique. Hegel 2022;N° 1:19-26. [DOI: 10.3917/heg.121.0019] [Reference Citation Analysis]
132 Gonzalez-chagolla A, Olivas-martinez A, Ruiz-manriquez J, Servín-rojas M, Kauffman-ortega E, Chávez-garcía LC, Juárez-león O, Cordova-gallardo J, Díaz-garcía JD, Gonzalez-huezo MS, Milanés-lizarraga G, Paez-zayas VM, Castillo-barradas M, Cobos-quevedo ODJ, García-juárez FI, Romero-lozanía JA, Toapanta-yanchapaxi L, Sánchez-avila JF, Avila-rojo JA, Bonilla-salas A, Dirthurbide-hernández M, Ruiz I, Valenzuela-vidales AK, García-juárez I. Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico. The Lancet Regional Health - Americas 2022;7:100151. [DOI: 10.1016/j.lana.2021.100151] [Reference Citation Analysis]
133 Chong N, Schoenberger H, Yekkaluri S, Fetzer DT, Rich NE, Yokoo T, Gopal P, Manwaring C, Quirk L, Singal AG. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther 2022;55:683-90. [PMID: 35170052 DOI: 10.1111/apt.16779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
134 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
135 Javaid N, Khan Z, Ali MA, Tahir SK. EVALUATING THE IMPACT OF EARLY NUTRITIONAL ASSESSMENT AND INTERVENTION IN HOSPITALIZED LIVER CIRRHOSIS PATIENTS. Arq Gastroenterol 2022;59:22-8. [DOI: 10.1590/s0004-2803.202200001-05] [Reference Citation Analysis]
136 Haworth JJ, Pitcher CK, Ferrandino G, Hobson AR, Pappan KL, Lawson JLD. Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath. Crit Rev Clin Lab Sci 2022;:1-20. [PMID: 35188863 DOI: 10.1080/10408363.2022.2038075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
137 Dubey SR, Ashavaid TF, Abraham P, Paradkar MU. Factors influencing circulating microRNAs as biomarkers for liver diseases. Mol Biol Rep. [DOI: 10.1007/s11033-022-07170-1] [Reference Citation Analysis]
138 Dalbeni A, Castelli M, Zoncapè M, Minuz P, Sacerdoti D. Platelets in Non-alcoholic Fatty Liver Disease. Front Pharmacol 2022;13:842636. [DOI: 10.3389/fphar.2022.842636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AM, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology 2022;162:621-44. [PMID: 34678215 DOI: 10.1053/j.gastro.2021.10.017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 49.0] [Reference Citation Analysis]
140 Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2022;20:e267-88. [PMID: 33387668 DOI: 10.1016/j.cgh.2020.12.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
141 Zhou K, Thompson LK, Liu L, Terrault NA, Cockburn MG. Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control. Cancer Causes Control. [DOI: 10.1007/s10552-022-01555-0] [Reference Citation Analysis]
142 Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D, Gebregziabher M. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. J GEN INTERN MED. [DOI: 10.1007/s11606-021-07341-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Solhi R, Lotfi AS, Lotfinia M, Farzaneh Z, Piryaei A, Najimi M, Vosough M. Hepatic stellate cell activation by TGFβ induces hedgehog signaling and endoplasmic reticulum stress simultaneously. Toxicol In Vitro 2022;:105315. [PMID: 35051607 DOI: 10.1016/j.tiv.2022.105315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Tapper EB, Kenney B, Nikirk S, Levine DA, Waljee AK. Animal Naming Test Is Associated With Poor Patient-Reported Outcomes and Frailty in People With and Without Cirrhosis: A Prospective Cohort Study. Clin Transl Gastroenterol 2022. [PMID: 35080516 DOI: 10.14309/ctg.0000000000000447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2022;76:195-201. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
146 Kim J, Yun YH, Jung Y. Therapeutic Potential of MicroRNAs and Their Nanoparticle-based Delivery in the Treatment of Liver Fibrosis. Biotechnologies for Gene Therapy 2022. [DOI: 10.1007/978-3-030-93333-3_1] [Reference Citation Analysis]
147 Gavurova B, Ivankova V. Alcohol and Cirrhosis. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_188-1] [Reference Citation Analysis]
148 Vinutha MR, Chandrika J, Krishnan B, Kokatnoor SA. Applying Ensemble Techniques for the Prediction of Alcoholic Liver Cirrhosis. Data Science and Security 2022. [DOI: 10.1007/978-981-19-2211-4_39] [Reference Citation Analysis]
149 Tapper EB, Fleming C, Rendon A, Fernandes J, Johansen P, Augusto M, Nair S. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies. Gastro Hep Advances 2022;1:1049-1087. [DOI: 10.1016/j.gastha.2022.06.016] [Reference Citation Analysis]
150 Suk KT, Koh H. New perspective on fecal microbiota transplantation in liver diseases. J Gastroenterol Hepatol 2022;37:24-33. [PMID: 34734433 DOI: 10.1111/jgh.15729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
151 Jia H. Metagenomics from bench to bedside and from bedside to bench. Investigating Human Diseases with the Microbiome 2022. [DOI: 10.1016/b978-0-323-91369-0.00006-6] [Reference Citation Analysis]
152 Zaidi S, Gough NR, Mishra L. Mechanisms and clinical significance of TGF-β in hepatocellular cancer progression. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.02.002] [Reference Citation Analysis]
153 Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in Chronic Liver Disease: An Update. J Clin Exp Hepatol 2022;12:937-47. [PMID: 34975241 DOI: 10.1016/j.jceh.2021.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
154 Garg S, Yadav E, Kaur R, Sasan A. Investigation of the influential factors for hepatic osteodystrophy in chronic liver disease: A case–control survey among the patients attending a tertiary care hospital in a rural region of Northern India. Tzu Chi Med J 2022;0:0. [DOI: 10.4103/tcmj.tcmj_27_22] [Reference Citation Analysis]
155 Gavurova B, Ivankova V. Alcohol and Cirrhosis. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-92392-1_188] [Reference Citation Analysis]
156 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Schoenberger H, Rich NE, Jones P, Yekkaluri S, Yopp A, Singal AG; Multi-Ethnic HCC Cohort Investigators. Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01351-3. [PMID: 34965448 DOI: 10.1016/j.cgh.2021.12.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
158 Basu E, Mehta M, Zhang C, Zhao C, Rosenblatt R, Tapper EB, Parikh NS. Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. J Neurol Sci 2021;434:120117. [PMID: 34959080 DOI: 10.1016/j.jns.2021.120117] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Plotogea OM, Gheorghe G, Stan-Ilie M, Constantinescu G, Bacalbasa N, Bungau S, Diaconu CC. Assessment of Sleep among Patients with Chronic Liver Disease: Association with Quality of Life. J Pers Med 2021;11:1387. [PMID: 34945859 DOI: 10.3390/jpm11121387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Randhawa NK, Shastri T, Hassanin EH, Randhawa S. Initial Presentation of Cirrhosis Mimicking an Ischemic Stroke. Cureus 2021;13:e19474. [PMID: 34912615 DOI: 10.7759/cureus.19474] [Reference Citation Analysis]
161 Fetzer DT, Browning T, Xi Y, Yokoo T, Singal AG. Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations. AJR Am J Roentgenol 2021. [PMID: 34910539 DOI: 10.2214/AJR.21.26735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
162 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
163 Tesfaye BT, Feyissa TM, Workneh AB, Gudina EK, Yizengaw MA. Chronic Liver Disease in Ethiopia with a Particular Focus on the Etiological Spectrums: A Systematic Review and Meta-Analysis of Observational Studies. Can J Gastroenterol Hepatol 2021;2021:8740157. [PMID: 34858892 DOI: 10.1155/2021/8740157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol 2021;75:1465-75. [PMID: 34437908 DOI: 10.1016/j.jhep.2021.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
165 Lazo M, Bilal U, Mitchell MC, Potter J, Hernaez R, Clark JM. Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clin Gastroenterol Hepatol 2021;19:2606-2614.e4. [PMID: 32882427 DOI: 10.1016/j.cgh.2020.08.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Bai W, Al-Karaghouli M, Stach J, Sung S, Matheson GJ, Abraldes JG. Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. Hepatology 2021;74:3301-15. [PMID: 34181770 DOI: 10.1002/hep.32033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
167 Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. Hepatology 2021;74:3330-44. [PMID: 34174003 DOI: 10.1002/hep.32032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
168 Abdullah AS, El Sayed IET, El-Torgoman AMA, Alghamdi NA, Ullah S, Wageh S, Kamel MA. Preparation and Characterization of Silymarin-Conjugated Gold Nanoparticles with Enhanced Anti-Fibrotic Therapeutic Effects against Hepatic Fibrosis in Rats: Role of MicroRNAs as Molecular Targets. Biomedicines 2021;9:1767. [PMID: 34944582 DOI: 10.3390/biomedicines9121767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
169 Wagle NS, Park S, Washburn D, Ohsfeldt RL, Rich NE, Singal AG, Kum HC. Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34796703 DOI: 10.1002/hep4.1863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
170 Simakina EN, Morozova TG. Improving the Algorithm for the Management of Patients with Viral Hepatitis Using Contrast-Free Hepatic Arterial Spin Labelling Magnetic Resonance Perfusion. Vestn rentgenol radiol 2021;102:276-283. [DOI: 10.20862/0042-4676-2021-102-5-276-283] [Reference Citation Analysis]
171 Zhang Y, Zhang Y, Zhang Y, Wang D, Peng F, Cui S, Yang Z. Ultrasonic image fibrosis staging based on machine learning for chronic liver disease. 2021 IEEE International Conference on Medical Imaging Physics and Engineering (ICMIPE) 2021. [DOI: 10.1109/icmipe53131.2021.9698912] [Reference Citation Analysis]
172 Keshvari S, Genz B, Teakle N, Caruso M, Cestari MF, Patkar OL, Tse BW, Sokolowski KA, Ebersbach H, Jascur J, Macdonald KPA, Miller G, Ramm GA, Pettit AR, Clouston AD, Powell EE, Hume DA, Irvine KM. Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease.. [DOI: 10.1101/2021.11.07.467663] [Reference Citation Analysis]
173 Scalon D, Picada JN, de Sousa JT, da Silva AT, Colares JR, Marroni NAP. Photobiomodulation intervention improves oxidative, inflammatory, and morphological parameters of skeletal muscle in cirrhotic Wistar rats. Lasers Med Sci 2021. [PMID: 34735658 DOI: 10.1007/s10103-021-03458-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Chang WH, Mueller SH, Tan YY, Lai AG. Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. Lancet Reg Health Eur 2021;10:100222. [PMID: 34806071 DOI: 10.1016/j.lanepe.2021.100222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
175 Mclean S, Yoshida EM, Sirpal S, Chandok N. A national paucity of hepatologists: An unprecedented opportunity for interdisciplinary collaboration. CanLivJ 2021;4:343-5. [DOI: 10.3138/canlivj-2021-0921] [Reference Citation Analysis]
176 Ruault C, Zappella N, Labreuche J, Cronier P, Claude B, Garnier M, Vieillard-Baron A, Ortuno S, Mallet M, Cosic O, Crosby L, Lesieur O, Pichon N, Galbois A, Bruel C, Ekpe K, Sauneuf B, Roux D, Legriel S. Identifying early indicators of secondary peritonitis in critically ill patients with cirrhosis. Sci Rep 2021;11:21076. [PMID: 34702902 DOI: 10.1038/s41598-021-00629-4] [Reference Citation Analysis]
177 Niezen S, Tapper EB, Trivedi H, Lai M, Curry MP, Mukamal KJ, Jiang ZG. Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults. Hepatol Commun 2021. [PMID: 34697916 DOI: 10.1002/hep4.1837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
179 Ma C, Qian AS, Nguyen NH, Stukalin I, Congly SE, Shaheen AA, Swain MG, Teriaky A, Asrani SK, Singh S. Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. Am J Gastroenterol 2021;116:2060-7. [PMID: 33998785 DOI: 10.14309/ajg.0000000000001292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
180 Mesropyan N, Kupczyk P, Isaak A, Endler C, Faron A, Dold L, Sprinkart AM, Pieper CC, Kuetting D, Attenberger U, Luetkens JA. Synthetic extracellular volume fraction without hematocrit sampling for hepatic applications. Abdom Radiol (NY) 2021;46:4637-46. [PMID: 34109447 DOI: 10.1007/s00261-021-03140-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
181 Tapper EB, Parikh ND. The Future of Quality Improvement for Cirrhosis. Liver Transpl 2021;27:1479-89. [PMID: 33887806 DOI: 10.1002/lt.26079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
182 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
183 Litwinowicz K, Waszczuk E, Gamian A. Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis. Nutrients 2021;13:3370. [PMID: 34684371 DOI: 10.3390/nu13103370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H. Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives. Mech Ageing Dev 2021;199:111572. [PMID: 34536446 DOI: 10.1016/j.mad.2021.111572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
185 Chao TY, Hsieh CC, Kuo YH, Yu YJ, Wan CH, Hsieh SC. Bracteanolide A abrogates oxidative stress-induced cellular damage and protects against hepatic ischemia and reperfusion injury in rats. Food Sci Nutr 2021;9:4758-69. [PMID: 34531989 DOI: 10.1002/fsn3.2374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Belykh MA. Impact of 4,4’-(propanediamide)Dibenzoate Sodium on Manifestations of Experimental Non-Alcoholic Steatohepatitis. BIOMEDICINE 2021;17:95-99. [DOI: 10.33647/2074-5982-17-3-95-99] [Reference Citation Analysis]
187 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Park JS, Ma H, Roh YS. Ubiquitin pathways regulate the pathogenesis of chronic liver disease. Biochem Pharmacol 2021;193:114764. [PMID: 34529948 DOI: 10.1016/j.bcp.2021.114764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Ezhilarasan D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis. J Cell Physiol 2021. [PMID: 34514599 DOI: 10.1002/jcp.30582] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
190 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
191 Ufere NN, Donlan J, Indriolo T, Richter J, Thompson R, Jackson V, Volandes A, Chung RT, Traeger L, El-Jawahri A. Burdensome Transitions of Care for Patients with End-Stage Liver Disease and Their Caregivers. Dig Dis Sci 2021;66:2942-55. [PMID: 32964286 DOI: 10.1007/s10620-020-06617-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
192 Tapper EB, Nikirk S, Parikh ND, Zhao L. Falls are common, morbid, and predictable in patients with cirrhosis. J Hepatol 2021;75:582-8. [PMID: 33887359 DOI: 10.1016/j.jhep.2021.04.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
193 Sahra S, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, Gumaste V. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. World J Hepatol 2021; 13(8): 926-938 [PMID: 34552699 DOI: 10.4254/wjh.v13.i8.926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Rudnick SR, Conway JD, Russo MW. Current state of endohepatology: Diagnosis and treatment of portal hypertension and its complications with endoscopic ultrasound. World J Hepatol 2021; 13(8): 887-895 [PMID: 34552695 DOI: 10.4254/wjh.v13.i8.887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
195 McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon-McGill S, Spencer HJ, Dranoff JA. Short-Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatol Commun 2021. [PMID: 34558847 DOI: 10.1002/hep4.1810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Siddiqui ATS, Parkash O, Hashmi SA. Malnutrition and liver disease in a developing country. World J Gastroenterol 2021; 27(30): 4985-4998 [PMID: 34497430 DOI: 10.3748/wjg.v27.i30.4985] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
197 Javaid N, Iqbal AZ, Hameeda M. NUTRITIONAL MANAGEMENT OF LIVER CIRRHOSIS AND ITS COMPLICATIONS IN HOSPITALIZED PATIENTS. Arq Gastroenterol 2021;58:246-52. [PMID: 34287534 DOI: 10.1590/S0004-2803.202100000-43] [Reference Citation Analysis]
198 Nathani P, Singal AG. Imaging and Biomarker Approaches to HCC Surveillance. Clin Liver Dis (Hoboken) 2021;17:401-4. [PMID: 34386203 DOI: 10.1002/cld.1066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Ma L, Khatib S, Craig AJ, Wang XW. Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-Cell Resolution. Semin Liver Dis 2021;41:321-30. [PMID: 34130336 DOI: 10.1055/s-0041-1729970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 O'Rourke C, Jayaraman S, El-Maraghi RH, Singal AG, Kielar AZ. Chronic Liver Disease and Liver Cancer: What the Hepatologists, Oncologists, and Surgeons Want to Know from Radiologists. Magn Reson Imaging Clin N Am 2021;29:269-78. [PMID: 34243916 DOI: 10.1016/j.mric.2021.05.001] [Reference Citation Analysis]
202 Wauquier F, Boutin-Wittrant L, Viret A, Guilhaudis L, Oulyadi H, Bourafai-Aziez A, Charpentier G, Rousselot G, Cassin E, Descamps S, Roux V, Macian N, Pickering G, Wittrant Y. Metabolic and Anti-Inflammatory Protective Properties of Human Enriched Serum Following Artichoke Leaf Extract Absorption: Results from an Innovative Ex Vivo Clinical Trial. Nutrients 2021;13:2653. [PMID: 34444810 DOI: 10.3390/nu13082653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
203 Misra AC, Eckhoff D. The development of artificial livers. Curr Opin Organ Transplant 2021. [PMID: 34325441 DOI: 10.1097/MOT.0000000000000907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
204 Neupane R, Taweesedt PT, Anjum H, Surani S. Current state of medical tourism involving liver transplantation-the risk of infections and potential complications . World J Hepatol 2021; 13(7): 717-722 [PMID: 34367493 DOI: 10.4254/wjh.v13.i7.717] [Reference Citation Analysis]
205 He Y, Guo X, Lan T, Xia J, Wang J, Li B, Peng C, Chen Y, Hu X, Meng Z. Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling. Stem Cell Res Ther 2021;12:396. [PMID: 34256837 DOI: 10.1186/s13287-021-02468-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
206 Brancale J, Vilarinho S. A single cell gene expression atlas of 28 human livers. J Hepatol 2021;75:219-20. [PMID: 34016468 DOI: 10.1016/j.jhep.2021.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
207 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
208 Shabbir A, Arshad M, Dar AJ, Khalid S. Pathophysiology and Diagnosis of Chronic Liver Disease. PJHS 2021. [DOI: 10.54393/pjhs.v2i01.22] [Reference Citation Analysis]
209 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
210 Rich NE, Noureddin M, Kanwal F, Singal AG. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. Lancet Gastroenterol Hepatol 2021;6:422-4. [PMID: 34015351 DOI: 10.1016/S2468-1253(21)00100-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
211 Melaram R. Environmental Risk Factors Implicated in Liver Disease: A Mini-Review. Front Public Health 2021;9:683719. [PMID: 34249849 DOI: 10.3389/fpubh.2021.683719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
212 Wong NZ, Mahmud N. The imperative for an updated cirrhosis surgical risk score. Ann Hepatol 2020;19:341-3. [PMID: 32474073 DOI: 10.1016/j.aohep.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
213 Abbasi U, Abbina S, Gill A, Takuechi LE, Kizhakkedathu JN. Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities. ACS Chem Biol 2021;16:945-72. [PMID: 34102834 DOI: 10.1021/acschembio.1c00122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
214 Desai AP, Greene M, Nephew LD, Orman ES, Ghabril M, Chalasani N, Menachemi N. Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders. Clin Transl Gastroenterol 2021;12:e00372. [PMID: 34142663 DOI: 10.14309/ctg.0000000000000372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Rajora N, De Gregorio L, Saxena R. Peritoneal Dialysis Use in Patients With Ascites: A Review. Am J Kidney Dis 2021:S0272-6386(21)00660-0. [PMID: 34144102 DOI: 10.1053/j.ajkd.2021.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
216 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
217 Enderes J, Teschke J, Manekeller S, Vilz TO, Kalff JC, Glowka TR. Chronic Liver Disease Increases Mortality Following Pancreatoduodenectomy. J Clin Med 2021;10:2521. [PMID: 34200183 DOI: 10.3390/jcm10112521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
218 Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken) 2021;17:365-70. [PMID: 34136143 DOI: 10.1002/cld.1061] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 38.0] [Reference Citation Analysis]
219 Knudsen C, Neyrinck AM, Leyrolle Q, Baldin P, Leclercq S, Rodriguez J, Beaumont M, Cani PD, Bindels LB, Lanthier N, Delzenne NM. Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice. J Nutr 2021;151:1507-16. [PMID: 33693866 DOI: 10.1093/jn/nxab032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
220 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 20.5] [Reference Citation Analysis]
221 Yang YY, Hsu YC. Effectiveness of sepsis bundle application and outcomes predictors to cirrhotic patients with septic shock. BMC Infect Dis 2021;21:483. [PMID: 34039297 DOI: 10.1186/s12879-021-06194-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Casler K, Chaney A. Cirrhosis: An evidence-based approach. Nursing 2021;51:24-34. [PMID: 33953095 DOI: 10.1097/01.NURSE.0000731828.24893.bb] [Reference Citation Analysis]
223 Drzewiecki K, Choi J, Brancale J, Leney-Greene MA, Sari S, Dalgiç B, Ünlüsoy Aksu A, Evirgen Şahin G, Ozen A, Baris S, Karakoc-Aydiner E, Jain D, Kleiner D, Schmalz M, Radhakrishnan K, Zhang J, Hoebe K, Su HC, Pereira JP, Lenardo MJ, Lifton RP, Vilarinho S. GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. J Exp Med 2021;218:e20201745. [PMID: 33956074 DOI: 10.1084/jem.20201745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
224 Haque L, Rosenheck R. Mental health and addiction service use among United States veterans with liver disease nationally in the Veterans Health Administration. JPMH 2021;20:191-200. [DOI: 10.1108/jpmh-07-2020-0088] [Reference Citation Analysis]
225 Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC, Singal AG. Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol Commun 2021;5:1481-9. [PMID: 34510836 DOI: 10.1002/hep4.1735] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
226 Moon AM, Mason MR, Galanko JA, Barritt AS, Bajaj JS. Periodontitis is associated with increased liver fibrosis in a population‐based cohort of US adults. GastroHep 2021;3:179-184. [DOI: 10.1002/ygh2.452] [Reference Citation Analysis]
227 Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transpl 2021;27:699-710. [PMID: 33226691 DOI: 10.1002/lt.25953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
228 Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu Y, Zhang S, Phillips JL, Hernaez R. Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-995.e1. [PMID: 32629122 DOI: 10.1016/j.cgh.2020.06.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
229 Bruno S, Herrera Sanchez MB, Chiabotto G, Fonsato V, Navarro-Tableros V, Pasquino C, Tapparo M, Camussi G. Human Liver Stem Cells: A Liver-Derived Mesenchymal Stromal Cell-Like Population With Pro-regenerative Properties. Front Cell Dev Biol 2021;9:644088. [PMID: 33981703 DOI: 10.3389/fcell.2021.644088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
230 Neyrinck AM, Sánchez CR, Rodriguez J, Cani PD, Bindels LB, Delzenne NM. Prebiotic Effect of Berberine and Curcumin Is Associated with the Improvement of Obesity in Mice. Nutrients 2021;13:1436. [PMID: 33923174 DOI: 10.3390/nu13051436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
231 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
232 Zeng J, Jing Y, Wu Q, Zeng J, Wei L, Liu J. Autophagy Is Required for Hepatic Differentiation of Hepatic Progenitor Cells via Wnt Signaling Pathway. Biomed Res Int 2021;2021:6627506. [PMID: 33928152 DOI: 10.1155/2021/6627506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Hu X, Shang G, Zhang J, Chen Z, Fu L, Li J, Lu X. Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e24530. [PMID: 33787570 DOI: 10.1097/MD.0000000000024530] [Reference Citation Analysis]
234 Ma C, Zhao M, Du Y, Jin S, Wu X, Zou H, Zhang Q, Gao L. Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury. Evid Based Complement Alternat Med 2021;2021:6661667. [PMID: 33747110 DOI: 10.1155/2021/6661667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
237 Magon KL, Parish JL. From infection to cancer: how DNA tumour viruses alter host cell central carbon and lipid metabolism. Open Biol 2021;11:210004. [PMID: 33653084 DOI: 10.1098/rsob.210004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
238 Goosmann L, Buchholz A, Bangert K, Fuhrmann V, Kluge S, Lohse AW, Huber S, Fischer L, Sterneck M, Huebener P. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int 2021;41:574-84. [PMID: 34542228 DOI: 10.1111/liv.14756] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
239 Iversen J, Peacock A, Price O, Byrne J, Dunlop A, Maher L. COVID-19 vaccination among people who inject drugs: Leaving no one behind. Drug Alcohol Rev 2021;40:517-20. [PMID: 33650174 DOI: 10.1111/dar.13273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
240 Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol 2021;74:567-77. [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024] [Cited by in Crossref: 251] [Cited by in F6Publishing: 257] [Article Influence: 125.5] [Reference Citation Analysis]
241 Taher M, Toossi MN, Jafarian A, Rasti A, Nayeri ND. Patients' Experiences of Life Challenges After Liver Transplantation: A Qualitative Study. J Patient Exp 2021;8:2374373521996956. [PMID: 34179375 DOI: 10.1177/2374373521996956] [Reference Citation Analysis]
242 Shao J, Liang Y, Li Y, Ding R, Zhu M, You W, Wang Z, Huang B, Wu M, Zhang T, Li K, Wu W, Wu L, Wang Q, Xia X, Wang S, Lu L. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatol Int. 2021;15:202-212. [PMID: 33548030 DOI: 10.1007/s12072-020-10123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
243 Xi S, Zheng X, Li X, Jiang Y, Wu Y, Gong J, Jie Y, Li Z, Cao J, Sha L, Zhang M, Chong Y. Activated Hepatic Stellate Cells Induce Infiltration and Formation of CD163+ Macrophages via CCL2/CCR2 Pathway. Front Med (Lausanne) 2021;8:627927. [PMID: 33614685 DOI: 10.3389/fmed.2021.627927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
244 Liu C, Sun Y, Yang Y, Feng Y, Xie X, Qi L, Liu K, Wang X, Zhu Q, Zhao X. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis. Eur Radiol 2021;31:5840-50. [PMID: 33533990 DOI: 10.1007/s00330-021-07702-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
245 Resino S, Fernández-Rodríguez A, Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Muñoz-Gómez MJ, Virseda-Berdices A, Martín-Vicente M, Martínez I, Jiménez-Sousa MA. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. J Clin Med 2021;10:483. [PMID: 33525598 DOI: 10.3390/jcm10030483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
247 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
248 Mokhtari F, Mohebbi SR, Sharifian A, Ramandi M, Razzaghi MR. Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases. Gastroenterol Hepatol Bed Bench 2021;14:S10-23. [PMID: 35154598] [Reference Citation Analysis]
249 Mahmud N, Fricker Z, Hubbard RA, Ioannou GN, Lewis JD, Taddei TH, Rothstein KD, Serper M, Goldberg DS, Kaplan DE. Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. Hepatology 2021;73:204-18. [PMID: 32939786 DOI: 10.1002/hep.31558] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
250 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:4-13. [PMID: 32319693 DOI: 10.1002/hep.31288] [Cited by in Crossref: 448] [Cited by in F6Publishing: 435] [Article Influence: 224.0] [Reference Citation Analysis]
251 Abid H, Cherkaoui H, Lahlali M, Lahmidani N, Ibrahimi SA, Abkari ME. What Impact Does COVID-19 Have in Cirrhotics? OJGas 2021;11:16-27. [DOI: 10.4236/ojgas.2021.111002] [Reference Citation Analysis]
252 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qiang T, Raman I, Li Q, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal A, Hoshida Y. A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. SSRN Journal. [DOI: 10.2139/ssrn.3760172] [Reference Citation Analysis]
253 Rai S, Sharma, B, Sharma M, More A. Review of clinical and preclinical studies on Ayurveda drugs used in management of liver diseases: A search for proof of concept. J Indian Sys Medicine 2021;9:226. [DOI: 10.4103/jism.jism_60_21] [Reference Citation Analysis]
254 Gajos A, Tapper EB. The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:518-23. [PMID: 33388173 DOI: 10.1016/j.clinthera.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
255 Macías-Rodríguez RU, Ruiz-Margáin A, Román-Calleja BM, Espin-Nasser ME, Flores-García NC, Torre A, Galicia-Hernández G, Rios-Torres SL, Fernández-del-Rivero G, Orea-Tejeda A, Lozano-Cruz OA. Effect of non-alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis. World J Hepatol 2020; 12(12): 1299-1313 [PMID: 33442456 DOI: 10.4254/wjh.v12.i12.1299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
256 Brancale J, Vilarinho S. A Single Cell Gene Expression Atlas of 28 Human Livers.. [DOI: 10.1101/2020.12.23.422515] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
257 Amponsah-Dacosta E, Tamandjou Tchuem C, Anderson M. Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome. World J Virol 2020; 9(5): 54-66 [PMID: 33362998 DOI: 10.5501/wjv.v9.i5.54] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
258 Tonon M, Piano S. Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. Clin Mol Hepatol 2021;27:94-6. [PMID: 33317236 DOI: 10.3350/cmh.2020.0305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
259 Matetic A, Contractor T, Mohamed MO, Bhardwaj R, Aneja A, Myint PK, Rakoski MO, Zieroth S, Paul TK, Mamas MA. Trends, management and outcomes of acute myocardial infarction in chronic liver disease. Int J Clin Pract 2021;75:e13841. [PMID: 33220158 DOI: 10.1111/ijcp.13841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
260 Rodríguez MJ, Herrera F, Donoso W, Castillo I, Orrego R, González DR, Zúñiga-Hernández J. Pro-Resolving Lipid Mediator Resolvin E1 Mitigates the Progress of Diethylnitrosamine-Induced Liver Fibrosis in Sprague-Dawley Rats by Attenuating Fibrogenesis and Restricting Proliferation. Int J Mol Sci 2020;21:E8827. [PMID: 33266360 DOI: 10.3390/ijms21228827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
261 Hung CC, Hsu YC, Lin KH. Comparing Mortality Risk Predictive Ability of Different Scoring Systems in Cirrhotic Patients with Bacteremia. Emerg Med Int 2020;2020:8596567. [PMID: 33163235 DOI: 10.1155/2020/8596567] [Reference Citation Analysis]
262 Bloom PP, Tapper EB. The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. J Clin Med 2020;9:E3620. [PMID: 33182743 DOI: 10.3390/jcm9113620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Kennedy P, Bane O, Hectors SJ, Fischman A, Schiano T, Lewis S, Taouli B. Noninvasive imaging assessment of portal hypertension. Abdom Radiol (NY) 2020;45:3473-95. [PMID: 32926209 DOI: 10.1007/s00261-020-02729-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
264 Taouli B, Alves FC. Imaging biomarkers of diffuse liver disease: current status. Abdom Radiol (NY) 2020;45:3381-5. [PMID: 32583139 DOI: 10.1007/s00261-020-02619-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
265 Silva JM, Silva MJ, Calinas F, Nogueira PJ. Burden of Liver Cirrhosis in Portugal between 2010 and 2017. GE Port J Gastroenterol 2021;28:153-61. [PMID: 34056037 DOI: 10.1159/000510729] [Reference Citation Analysis]
266 Nadi A, Moradi L, Ai J, Asadpour S. Stem Cells and Hydrogels for Liver Tissue Engineering: Synergistic Cure for Liver Regeneration. Stem Cell Rev and Rep 2020;16:1092-104. [DOI: 10.1007/s12015-020-10060-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
267 Nouri-Vaskeh M, Khalili N, Khalaji A, Behnam P, Alizadeh L, Ebrahimi S, Gilani N, Mohammadi M, Madinehzadeh SA, Zarei M. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Arch Physiol Biochem 2020;:1-6. [PMID: 33043692 DOI: 10.1080/13813455.2020.1828479] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
269 Grissa D, Nytoft Rasmussen D, Krag A, Brunak S, Juhl Jensen L. Alcoholic liver disease: A registry view on comorbidities and disease prediction. PLoS Comput Biol 2020;16:e1008244. [PMID: 32960884 DOI: 10.1371/journal.pcbi.1008244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
270 Jung I, Kim H, Moon S, Lee H, Kim B. Overview of Salvia miltiorrhiza as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action. Antioxidants (Basel) 2020;9:E857. [PMID: 32933217 DOI: 10.3390/antiox9090857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
271 Stepanyan IA, Izranov VA, Gordova VS, Beleckaya MA, Stepanyan SA. INTRA- AND INTER-RESEARCH REPRODUCIBILITY OF LINEAR LIVER MEASUREMENTSBY ULTRASOUND EXAMINATION. Lučevaâ diagn ter 2020;11:73-81. [DOI: 10.22328/2079-5343-2020-11-3-73-81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
272 Kardashian A, Patel AA, Aby ES, Cusumano VT, Soroudi C, Winters AC, Wu E, Beah P, Delshad S, Kim N, Yang L, May FP. Identifying Quality Gaps in Preventive Care for Outpatients With Cirrhosis Within a Large, Academic Health Care System. Hepatol Commun 2020;4:1802-11. [PMID: 33305151 DOI: 10.1002/hep4.1594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
273 Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol 2020;73:705-8. [PMID: 32446714 DOI: 10.1016/j.jhep.2020.05.013] [Cited by in Crossref: 159] [Cited by in F6Publishing: 165] [Article Influence: 53.0] [Reference Citation Analysis]
274 Chan SL, Kudo M. Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. Liver Cancer 2020;9:491-502. [PMID: 33078127 DOI: 10.1159/000510765] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
275 Yang JY, Moon AM, Kim H, Pate V, Barritt AS 4th, Crowley MJ, Buse JB, Stürmer T, Alexopoulos AS. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. J Diabetes Complications 2020;34:107706. [PMID: 32843283 DOI: 10.1016/j.jdiacomp.2020.107706] [Reference Citation Analysis]
276 Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;52:701-9. [PMID: 32598091 DOI: 10.1111/apt.15917] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
277 Petkau VV, Breder VV, Bessonova EN, Laktionov KK, Stilidi IS. Oncological care for the patients with hepatocellular carcinoma in COVID-19 pandemic. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-9-226-231] [Reference Citation Analysis]
278 An S, Jang E, Lee JH. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evid Based Complement Alternat Med 2020;2020:8761435. [PMID: 32802138 DOI: 10.1155/2020/8761435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
279 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
280 Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget 2020;11:2686-701. [PMID: 32733642 DOI: 10.18632/oncotarget.27647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
281 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
282 Cullaro G, Asrani SK. Not All Episodes of Acute Kidney Injury Are Equal in Patients With Cirrhosis, Based on Patterns of Renal Dysfunction. Clin Gastroenterol Hepatol 2020;18:1694-5. [PMID: 32184186 DOI: 10.1016/j.cgh.2020.03.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
283 Karstensen JG, Ebigbo A, Bhat P, Dinis-Ribeiro M, Gralnek I, Guy C, Le Moine O, Vilmann P, Antonelli G, Ijoma U, Anigbo G, Afiheni M, Duduyemi B, Desalegn H, De Franchis R, Ponchon T, Hassan C, Aabakken L. Endoscopic treatment of variceal upper gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline. Endosc Int Open 2020;8:E990-7. [PMID: 32626821 DOI: 10.1055/a-1187-1154] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
284 Huang H, Chen H, Hsu Y. Comparing the Prognosis of Patient with Alcohol and Nonalcohol-Associated Cirrhosis with Bacteremia. Alcohol and Alcoholism 2020;55:512-7. [DOI: 10.1093/alcalc/agaa057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
285 Arshad M, Asif H, John A, Pasha MO. Chronic Liver Disease and it’s Complications. MJZ 2020. [DOI: 10.54393/mjz.v1i1.7] [Reference Citation Analysis]
286 Chu H, Jiang L, Gao B, Gautam N, Alamoudi JA, Lang S, Wang Y, Duan Y, Alnouti Y, Cable EE, Schnabl B. The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res 2021;227:1-14. [PMID: 32553670 DOI: 10.1016/j.trsl.2020.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
287 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
288 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020; 12(5): 220-229 [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
289 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
290 Foster C, Baki J, Nikirk S, Williams S, Parikh ND, Tapper EB. Comprehensive Health-State Utilities in Contemporary Patients With Cirrhosis. Hepatol Commun 2020;4:852-8. [PMID: 32490321 DOI: 10.1002/hep4.1512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
291 Bodtger U, Hallifax RJ. Epidemiology: why is pleural disease becoming more common? Pleural Disease 2020. [DOI: 10.1183/2312508x.10022819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
292 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 25.3] [Reference Citation Analysis]
293 Patel H, Balar B, Irigela M, Vootla V, Chandrala C, Hashmi H, Abdulsamad M, Makker J. Risk Factors for Liver Cirrhosis-Related Readmissions in the Largest Ethnic Minority in United States. Gastroenterology Res 2020;13:11-8. [PMID: 32095168 DOI: 10.14740/gr1227] [Reference Citation Analysis]
294 Trivedi HD, Danford CJ, Goyes D, Bonder A. Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges. Clin Exp Gastroenterol 2020;13:17-24. [PMID: 32021374 DOI: 10.2147/CEG.S204638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
295 Nouri-Vaskeh M, Malek Mahdavi A, Afshan H, Alizadeh L, Zarei M. Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phytother Res 2020;34:1446-54. [PMID: 32017253 DOI: 10.1002/ptr.6620] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
296 Meadows V, Kennedy L, Kundu D, Alpini G, Francis H. Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. Front Med (Lausanne) 2020;7:15. [PMID: 32064266 DOI: 10.3389/fmed.2020.00015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
297 da Silva Meirelles L, Marson RF, Solari MIG, Nardi NB. Are Liver Pericytes Just Precursors of Myofibroblasts in Hepatic Diseases? Insights from the Crosstalk between Perivascular and Inflammatory Cells in Liver Injury and Repair. Cells 2020;9:E188. [PMID: 31940814 DOI: 10.3390/cells9010188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
298 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
299 Sundaram B, Behnke K, Belancic A, Al-Salihi MA, Thabet Y, Polz R, Pellegrino R, Zhuang Y, Shinde PV, Xu HC, Vasilevska J, Longerich T, Herebian D, Mayatepek E, Bock HH, May P, Kordes C, Aghaeepour N, Mak TW, Keitel V, Häussinger D, Scheller J, Pandyra AA, Lang KS, Lang PA. iRhom2 inhibits bile duct obstruction-induced liver fibrosis. Sci Signal 2019;12:eaax1194. [PMID: 31662486 DOI: 10.1126/scisignal.aax1194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
300 Petrasek J, Singal AG, Rich NE. Harms of hepatocellular carcinoma surveillance. Curr Hepatol Rep 2019;18:383-9. [PMID: 33214987 DOI: 10.1007/s11901-019-00488-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]